- Trial Phase
- Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled
- Time to Market
- Potential U.S. launch as soon as H1 2028 if Q1 2027 ACHIEVE topline data support a Q3 2027 Accelerated-Approval BLA (company guidance); otherwise later or never.
- Why 7/10
- The next hard, dated catalyst is the topline readout of the fully-enrolled (71-participant) registrational expansion cohort of the Phase 1/2 ACHIEVE trial, guided for Q1 2027 (~5-8 months out), which would support a potential U.S. Accelerated-Approval BLA in Q3 2027; because it is a pivotal-class binary on a lead asset at a company that also runs other programs (DMD drug z-rostudirsen with a Jan 21, 2027 PDUFA), impactScore is 7, not 8+.
The single binary to watch for THIS drug is the ACHIEVE topline readout in Q1 2027 — a strong result supports a Q3 2027 accelerated-approval BLA and a potential H1 2028 U.S. launch; a weak result would hit a ~$3.9B market cap hard. Note the stock may also trade on Dyne's OTHER drug (z-rostudirsen DMD PDUFA Jan 21, 2027) before the DM1 readout, and watch for any 2026 conference data previews.
Price Chart
Executive Summary
z-basivarsen is Dyne Therapeutics' (Nasdaq: DYN) lead drug for myotonic dystrophy type 1 (DM1), an antisense-oligonucleotide therapy that targets the toxic RNA driving the disease. Dyne announced in June 2026 that the registrational expansion cohort of the Phase 1/2 ACHIEVE trial was fully enrolled (71 participants), with topline data guided for Q1 2027, a potential U.S. Accelerated-Approval BLA in Q3 2027, and a potential launch in H1 2028; a Phase 3 confirmatory trial (HARMONIA) is already running. The company has no approved products, so this readout is a defining binary, balanced against a fully-funded balance sheet (cash runway into Q2 2028), strong analyst consensus (mean target ~$39.5 vs ~$25 share price), but also meaningful competition (Avidity's del-desiran Phase 3 DM1 trial has an earlier estimated primary completion of Aug 2026), recent dilution, insider selling, and ~13% short interest.
How It Works
z-basivarsen is an antisense-oligonucleotide medicine — the "-arsen" in its name identifies that drug class (short synthetic nucleic-acid strands that bind and neutralize disease-causing RNA). It is being developed for myotonic dystrophy type 1 (DM1), a genetic disease in which toxic RNA damages muscle and other tissues; the drug is designed to reduce that toxic RNA in muscle, where DM1 does most of its harm, and is given as a repeat infusion.
Trial Status
The registrational expansion cohort of the Phase 1/2 ACHIEVE trial in myotonic dystrophy type 1 (DM1) completed enrollment with 71 participants on June 3, 2026; topline data are planned for Q1 2027 to support a potential BLA for U.S. Accelerated Approval in Q3 2027. The Phase 3 HARMONIA trial, which assesses multi-system efficacy, safety and tolerability, was initiated in March 2026.
The Two-Sided Case
Upcoming Catalysts
- ACHIEVE registrational-cohort topline data (DM1) — guided Q1 2027
- Potential BLA submission for U.S. Accelerated Approval — Q3 2027 (if data support)
- Phase 3 HARMONIA enrollment progress and interim updates
- Company-level watch (different drug): z-rostudirsen DMD BLA PDUFA target date Jan 21, 2027 — could move DYN sentiment broadly
- Possible conference data previews in H2 2026 ahead of the Q1 2027 readout
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Dyne Therapeutics, Inc. PRESS-RELEASE DYN ·Originating report